奥密克戎感染后新冠后症状及加强接种效果:一项基于人群的队列研究
该研究基于挪威四项问卷队列与全国健康登记数据,纳入超过31,000名未感染者和26,000名奥密克戎感染者,评估感染后3-5个月22种症状的超额风险。结果显示,近期接种加强针者感染后新发症状的超额风险低于仅接种两剂者,神经认知和心肺症状风险降低最明显。
要点
- 感染前近期接种加强针者,感染后3-5个月新发症状超额风险女性为7%、男性最高5%。
- 仅接种两剂者超额风险女性最高15%、男性最高9%,加强针降低风险。
- 记忆差、脑雾和疲劳在近期加强接种后风险差异最大。
核心结论
- 感染前近期接种加强针大幅降低了奥密克戎感染至少3个月后发生的神经认知和心肺症状。
研究设计与样本
- 基于四项问卷队列与全国健康登记链接的基于人群的前瞻性研究。
- 纳入挪威母亲、父亲和儿童队列、挪威流感妊娠队列、老年队列和青年成人队列中11-80岁女性与男性参与者。
- 研究样本包括超过31,000名未感染者和26,000名奥密克戎感染者。
- 感染者中12%在首次感染前超过130天(中位数154天)接种两剂但未接种第三剂,76%已接种第三剂(加强)剂(中位数感染前40天)。
主要发现
- 仅接种两剂者感染后新发症状超额风险女性最高15%、男性最高9%。
- 近期接种加强针的感染者对应超额风险女性为7%、男性最高5%。
- 近期加强接种后风险差异最大的症状为记忆差、脑雾和疲劳。
- 新冠后症状在青年和中年成人中比青少年和老年组更常检出。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The impact of vaccination on the type and risk of specific post-COVID symptoms after Omicron infection is not clear. We aimed to investigate the excess risk and patterns of 22 symptoms 3-5 months after Omicron infection, comparing uninfected and infected subjects with and without recent booster vaccination. METHODS: We conducted a population-based prospective study based on four questionnaire-based cohorts linked to national health registries. Our study includes female and male participants aged 11-80 years from The Norwegian Mother, Father, and Child Cohort Study, The Norwegian Influenza Pregnancy Cohort, The Senior Cohort, and The Young Adult Cohort. All participants registered presence of 22 COVID-related symptoms irrespective of infection and vaccination status. RESULTS: The study sample includes more than 31,000 uninfected and 26,000 Omicron infected subjects. Among infected subjects, 12 % were vaccinated with two doses >130 days before the primary infection (median 154 days) but had not received a third dose, while 76 % had received a third (booster) dose (median 40 days before infection). Among those with two doses only, the excess risk for new symptoms after infection (vs. no infection) were up to 15 % for women and 9 % for men. Among infected subjects with recent booster dose, the corresponding excess risks were 7 % among women and up to 5 % among men. The largest risk differences after recent booster vaccination were seen for poor memory, brain fog, and fatigue. Post-COVID symptoms were more often detected among young and middle-aged adults than among adolescents and older age groups. CONCLUSION: Recent booster vaccination before infection substantially reduced both neurocognitive and cardiorespiratory symptoms occurring at least 3 months after Omicron infection.
引用
- Caspersen IH, Skodvin SN, Blix K, et al. Post-COVID symptoms after SARS-CoV-2 omicron infection and the effect of booster vaccination: A population-based cohort study. Vaccine. 2025. PMID: 39787799. doi:10.1016/j.vaccine.2024.126664
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。